Withholding ARBs After Surgery Linked to Higher Mortality

Share this content:
Withholding ARBs After Surgery Linked to Higher Mortality
Withholding ARBs After Surgery Linked to Higher Mortality

(HealthDay News) -- For veterans regularly prescribed angiotensin receptor blockers (ARBs) admitted for noncardiac surgery, failure to resume ARB therapy by postoperative day two is associated with increased mortality risk, according to a study published online May 30 in Anesthesiology.

Susan M. Lee, M.D., from the University of California in San Francisco, and colleagues conducted a retrospective cohort study to examine patterns of postoperative ARB use in veterans regularly prescribed ARBs who were admitted for noncardiac surgery between 1999 and 2011. The authors assessed the effect of failure to resume ARBs by postoperative day two on all-cause 30-day mortality. Data were included for 30,173 inpatient surgical admissions.

The researchers found that approximately 33.8 percent of patients did not resume ARBs by postoperative day two. The 30-day mortality rate was 1.3 percent for those who resumed ARBs, compared with 3.2 percent for those who had ARBs withheld (multivariable adjusted hazard ratio, 1.74; P < 0.001). In a propensity score-matched subset of 19,490 patients, the hazard ratio was similar (hazard ratio, 1.47; P < 0.001). The mortality risk was increased in younger patients who did not resume ARBs (hazard ratio, 2.52; P < 0.001 for those younger than 60 years) compared with older patients (hazard ratio, 1.42; P < 0.01 for patients aged older than 75 years).

"Withholding ARBs is strongly associated with increased 30-day mortality, especially in younger patients, although residual confounding may be present," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »